Cefminox API Manufacturers & Suppliers

Cefminox (CAS number 84305-41-9) is a second-generation cephalosporin antibiotic belonging to the cephamycin subclass of beta-lactams. Chemically, it contains the cephalosporin nucleus with a characteristic alkyloxy group attached at the C6 carbon position, contributing to its antibacterial profile. Cefminox is structurally defined by the fused bicyclic ring system common to cephalosporins and exhibits sulfur and thiazine heterocyclic components typical of this class.

Clinically, Cefminox is approved for use in Japan, although detailed formal indications have not been widely specified in the literature. Its classification as a second-generation cephalosporin suggests activity primarily against aerobic gram-negative bacteria and some gram-positive organisms, consistent with the known spectrum of other compounds in this category. Like other cephamycins, Cefminox may have enhanced stability against certain beta-lactamases.

The mechanism of action aligns with that of beta-lactam antibiotics, involving inhibition of bacterial cell wall synthesis. This occurs through binding to penicillin-binding proteins (PBPs), which disrupts peptidoglycan cross-linking essential for cell wall structural integrity and ultimately leads to bacterial cell lysis.

Pharmacokinetic data, including absorption, distribution, metabolism, and excretion parameters, are limited in publicly available sources. However, cephamycins generally demonstrate moderate bioavailability when administered parenterally and are primarily eliminated renally, which warrants monitoring in patients with renal impairment. Cefminox is recognized to possess nephrotoxic potential, a safety consideration relevant to clinical and preclinical use.

While not widely marketed internationally, Cefminox has appeared under experimental and clinical contexts primarily within Japan. Its use requires careful attention to regulatory approvals and adherence to local pharmacopeial standards.

For API procurement, sourcing should focus on suppliers that provide comprehensive quality documentation, including certificates of analysis conforming to relevant international standards such as ICH Q7 and GMP guidelines. Given its chemical class and potential nephrotoxicity, rigorous impurity profiling and stability data are essential to ensure safe formulation and clinical application.